European leader in clinical testing laboratories, held its Shareholders’ Meeting today in Geneva. 11'610’100 registered shares, totalling 98.6 % of the company’s voting rights, were represented.

The Shareholders’ Meeting approved the following resolutions:

• the management report, the annual financial statements and the Group’s financial statements for the 2006/2007 fiscal year. Unilabs posted revenues of CHF 313.9 million, up 7.8 % on the previous year
• the carry-forward of the profits of CHF 1,492,829 available at May 31, 2007
• the Board of Directors’ proposal to discharge its members for the 2006/2007 fiscal year
• the re-election of Alex Hoffmann and Patrick Schellenberg, and the election of Paul Hökfelt, Frederik Näslund and Simon Lindfors, to the Board of Directors for a one-year mandate
• the re-election of Ernst & Young SA as Statutory Auditor of the Group’s consolidated financial statements until the next Annual Shareholders’ Meeting
• the amendments to the company’s articles of association, and especially Articles 6 and 31, and the abrogation of Article 22

Following the Shareholders’ Meeting, the Board of Directors of Unilabs designated Paul Hökfelt as Chairman of the Board of Direction of Unilabs SA.

About Unilabs
The Unilabs Group (SWX: ULB) is the European leader of clinical testing laboratories. With over 50 laboratories and over 1800 employees operating in 6 countries, Unilabs tests over 3.5 million samples per year using more than 1500 different tests. Unilabs’ clinical testing services are used by over 60 public and private hospitals in France, Spain and Switzerland. Unilabs has been listed on the SWX Swiss Stock Exchange since 1997.

For further information, please contact
Christophe Lamps, (tel.             +4122718 37 46        or             +4179 476 26 87       ;
mail: clamps@rochat-pr.ch.

Our press releases are also available on the Internet at our website www.unilabs.com.